{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:39:33Z","timestamp":1790667573959,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["222300420534"],"award-info":[{"award-number":["222300420534"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["222102310106"],"award-info":[{"award-number":["222102310106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Program","award":["SBGJ2020002081"],"award-info":[{"award-number":["SBGJ2020002081"]}]},{"name":"Medical Research Program","award":["LHGJ20190249"],"award-info":[{"award-number":["LHGJ20190249"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Studies are needed to assess risk factors pertinent to the incidence of secondary malignancies among childhood and adolescent lymphoma survivors. We aimed to identify risk factors pertinent to the incidence of secondary malignancies and subsequently establish a clinically practical predictive nomogram.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 5561 patients who were diagnosed with primary lymphoma below the age of 20 years between 1975 and 2013 and survived for at least 5 years were identified. Standardized incidence ratio (SIR) and excess risk (ER) analysis were performed by sex, age, and year when primary lymphoma was diagnosed, sites and types of primary lymphoma, and therapy strategies. Univariable and multivariable logistic regression were used to identify independent risk factors for adolescent and childhood lymphoma-related secondary malignancies. Based on 5 factors (age, time from lymphoma diagnosis, gender, lymphoma type, and therapy), a nomogram for predicting the risk of a secondary malignancy for patients with childhood and adolescent primary lymphoma was established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 5561 lymphoma survivors, 424 developed a secondary malignancy. Females (SIR = 5.34, 95% CI, 4.73-5.99; ER = 50.58) exhibited a higher SIR and ER than males (SIR = 3.28, 95% CI, 2.76-3.87; ER = 15.53). Blacks were at a higher risk than Caucasians or others. Nodular lymphocyte-predominant Hodgkin lymphoma survivors exhibited typically high SIR (13.13, 95% CI, 6-24.92) and ER (54.79) among all lymphoma classifications. Lymphoma survivors who underwent radiotherapy, whether they received chemotherapy or not, had typically higher SIR and ER. Among all types of secondary malignancies, \u201cbone and joint neoplasms\u201d (SIR = 11.07, 95% CI, 5.52-19.81) and \u201csoft tissue neoplasms\u201d (SIR = 12.27, 95% CI, 7.59-18.76) presented significantly high SIR whereas \u201cbreast cancer\u201d and \u201cendocrine cancer\u201d associated with higher ER. The median diagnosis age of secondary malignancies was 36 years old, and the median time interval between the diagnosis of two malignancies was 23 years. A nomogram was constructed to predict the risk of secondary malignancies in patients diagnosed with primary lymphoma before 20 years of age. After internal validation, the AUC and C-index of the nomogram are 0.804 and 0.804, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion and Relevance<\/jats:title>\n                  <jats:p>The established nomogram provides a convenient and reliable tool for predicting the risk of a secondary malignancy among childhood and adolescent lymphoma survivors, concluding significant concern for lymphoma survivors with high-risk estimates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad112","type":"journal-article","created":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T10:07:44Z","timestamp":1683972464000},"page":"e765-e773","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram"],"prefix":"10.1093","volume":"28","author":[{"given":"Junqi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Erqi, Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Erqi, Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimha M","family":"Beeraka","sequence":"additional","affiliation":[{"name":"Raghavendra Institute of Pharmaceutical Education and Research (RIPER) , Anantapuramu, Chiyyedu, Andhra Pradesh , India"},{"name":"Department of Human Anatomy, I.M. Sechenov First Moscow State Medical University (Sechenov University) , Moscow , Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Erqi, Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Erqi, Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Erqi, Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[{"name":"Endocrinology Department, The First Affiliated Hospital of Zhengzhou University , Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitai","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Erqi, Zhengzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"issue":"16","key":"2023090805133200600_CIT0001","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.3390\/cancers13163956","article-title":"A population-based analysis of 30-year mortality among five-year survivors of adolescent and young adult cancer: the roles of primary cancer, subsequent malignancy, and oth","volume":"13","author":"Moke","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"2023090805133200600_CIT0002","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","article-title":"Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study","volume":"27","author":"Armstrong","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023090805133200600_CIT0003","first-page":"1","article-title":"Deaths: final data for 2","author":"Murphy","year":"2015"},{"issue":"2","key":"2023090805133200600_CIT0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2023090805133200600_CIT0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.29685","article-title":"Increased risk of second malignant neoplasms in adolescents and young adults with cancer","volume":"122","author":"Lee","year":"2016","journal-title":"Cancer"},{"issue":"20","key":"2023090805133200600_CIT0006","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2016.71.6902","article-title":"Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy","volume":"35","author":"Teepen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"101032","key":"2023090805133200600_CIT0007","first-page":"1","article-title":"Risk of late mortality and second malignant neoplasms among 5-year survivors of young adult cancer: a report of the childhood, adolescent, and young adult cancer survivors research program","volume":"2012","author":"Zhang","year":"2012","journal-title":"J Cancer Epidemiol"},{"issue":"11","key":"2023090805133200600_CIT0008","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdf289","article-title":"Long-term risk of second malignancy after treatment of Hodgkin\u2019s disease: the influence of treatment, age and follow-up time","volume":"13","author":"Abrahamsen","year":"2002","journal-title":"Ann Oncol"},{"key":"2023090805133200600_CIT0009","author":"Surveillance, E., and End Results (SEER) Program"},{"key":"2023090805133200600_CIT0010","volume-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000","author":"Curtis","year":"2006"},{"key":"2023090805133200600_CIT0011","volume-title":"International Classification of Diseases for Oncology","author":"Fritz","year":"2000","edition":"3"},{"key":"2023090805133200600_CIT0012","volume-title":"International Classification of Diseases for Oncology: ICD-O","author":"Jack","year":"2000"},{"key":"2023090805133200600_CIT0013","author":"SEER: Surveillance, E., and End Results Program"},{"issue":"7","key":"2023090805133200600_CIT0014","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/bimj.4710350716","article-title":"Confidence i","volume":"35","author":"Sahai","year":"1993","journal-title":"Biometrical J."},{"key":"2023090805133200600_CIT0015","volume-title":"Statistics in Epidemiology: Methods, Techniques, and Applications","author":"Sahai","year":"1996"},{"key":"2023090805133200600_CIT0016","author":"SEER*Stat"},{"key":"2023090805133200600_CIT0017","first-page":"4386","article-title":"High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin\u2019s disease: report from the Late Effects Study Group","volume-title":"J Clin Oncol","author":"Bhatia","year":"2003"},{"issue":"2","key":"2023090805133200600_CIT0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0889-8588(18)30247-8","article-title":"Solid second cancers following Hodgkin\u2019s disease","volume":"7","author":"Tucker","year":"1993","journal-title":"Hematol Oncol Clin North Am"},{"key":"2023090805133200600_CIT0019","first-page":"103032","article-title":"Risk of late mortality and second malignant Neoplasms among 5-year survivors of young adult cancer: a report of the childhood, adolescent, and young adult cancer survivors research program","volume-title":"J Cancer Epidemiol","author":"Zhang","year":"2012"},{"issue":"1","key":"2023090805133200600_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-020-00379-y","article-title":"Nomograms based on SUVmax of 18F-FDG PET\/CT and clinical parameters for predicting \u00adprogression-free and overall survival in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma","volume":"21","author":"Li","year":"2021","journal-title":"Cancer Imag"},{"key":"2023090805133200600_CIT0021","first-page":"402","article-title":"A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study","volume-title":"Br J Cancer","author":"Cai","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e765\/51436957\/oyad112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e765\/51436957\/oyad112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:13:56Z","timestamp":1694150036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/9\/e765\/7161526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5,13]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad112","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,5,13]]}}}